Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 4/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.49 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.49 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | ATM | Q13315 | 2/20 | 0.45 |
| ▸ | FLT1 | P17948 | 1/20 | 0.43 |
| ▸ | FLT4 | P35916 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ACR | P10323 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9187752 | 0.89 | SMN1; SMN2 (0.59) | SMN1; SMN2HTTNPC1RAB9ATAS1R3 | |
| SCHEMBL22859136 | 0.84 | FLT1 (0.46) | SMN1; SMN2HTTNPC1RAB9AKMT2A | |
| SCHEMBL22859142 | 0.84 | FLT1 (0.46) | SMN1; SMN2HTTNPC1RAB9AKMT2A | |
| SCHEMBL22859172 | 0.84 | FLT1 (0.46) | SMN1; SMN2HTTNPC1RAB9AKMT2A | |
| SCHEMBL5856133 | 0.80 | HPGD (0.58) | SMN1; SMN2NPC1RAB9AKMT2AHPGD | |
| SCHEMBL4156165 | 0.80 | SMN1; SMN2 (0.64) | SMN1; SMN2HTTNPC1RAB9ATAS1R3 | |
| SCHEMBL10602569 | 0.80 | SMN1; SMN2 (0.64) | SMN1; SMN2HTTNPC1RAB9ATAS1R3 | |
| SCHEMBL24386356 | 0.80 | LMNA (0.56) | SMN1; SMN2NPC1RAB9AKMT2AHDAC1 | |
| SCHEMBL5800429 | 0.80 | LMNA (0.56) | SMN1; SMN2NPC1RAB9AKMT2AHDAC1 | |
| SCHEMBL15296551 | 0.77 | TAS1R3 (0.52) | SMN1; SMN2HTTNPC1RAB9ATAS1R3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7144906-B2 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2006-12-05 | — | — | US | disclosed |
| US-7030143-B2 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2006-04-18 | — | — | US | disclosed |
| US-7022723-B2 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2006-04-04 | — | — | US | disclosed |
| EP-1634876-A2 | Heterocyclic compounds for the treatment of hyperlipidemia agents | Nippon Shinyaku Co., Ltd. (JP) | 2006-03-15 | — | — | EP | disclosed |
| US-6998412-B2 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2006-02-14 | — | — | US | disclosed |
| US-20050009892-A1 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2005-01-13 | — | — | US | disclosed |
| US-20050009785-A1 | Heterocyclic compounds | KUWABARA KENJI (JP) | 2005-01-13 | — | — | US | disclosed |
| US-20040162325-A1 | Heterocyclic compounds | KUWABARA KENJI (JP) | 2004-08-19 | — | — | US | disclosed |
| US-20030166697-A1 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2003-09-04 | — | — | US | disclosed |
| EP-1295875-A1 | HETEROCYCLIC COMPOUNDS | Nippon Shinyaku Co., Ltd. (JP) | 2003-03-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009785-A1 | Heterocyclic compounds | LIPC, GPR119, APOB | SMN1; SMN2 4207/4885HTT 405/4885NPC1 32/4885 |
| US-20050009892-A1 | Heterocyclic compounds | GPR119, LIPC, LIPE | SMN1; SMN2 4287/4885HTT 487/4885NPC1 40/4885 |
| US-20040162325-A1 | Heterocyclic compounds | LIPE, GPR119, LIPC | SMN1; SMN2 4370/4885HTT 417/4885NPC1 63/4885 |
| US-20030166697-A1 | Heterocyclic compounds | LIPE, GPR119, LIPC | SMN1; SMN2 4370/4885HTT 417/4885NPC1 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.